Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

TD Cowen analyst Ritu Baral maintained a Hold rating on Sarepta Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $20.08. According to TipRanks.com, Baral ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Provided by PR NewswireJul 1, 2025, 8:00:00 PM SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity ...

Review the current valuation for Sarepta Therapeutics Inc (SRPT:XMEX) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, ...

In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics SRPT, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the Massive Sell-Offs: These 10 Stocks Shockingly Nosedived. Sarepta Therapeutics slashed its share price by 44 percent last week following price ...

In a market note, Oppenheimer significantly lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $45 from $123 previously, marking a 63-percent downside.